Archives of disease in childhood · 2026
Use of subcutaneous epinephrine in addition to standard first-line treatment with short-acting β2-agonist and systemic steroids in children and adolescents with an acute severe asthma exacerbation: a systematic review of randomised controlled trials.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mudawi Khalid, Hamud Ali, Powell Colin, Alnasif Naim, Alsaleh Salah, Tonbari Amjad, Salem Ramadan, Zou Zou Aiman, Alhaji Adham, Pullattayil Abdul Kareem, Abdelgadir Ibtihal Siddiq
Аннотация
IMPORTANCE: Asthma is a common chronic disease with significant morbidity and mortality.
OBJECTIVES: To assess the safety and efficacy of subcutaneous epinephrine in addition to the standard first-line treatment of acute asthma in children.
DATA SOURCE AND STUDY SELECTION: The following databases were inspected from 1966 to 22 June 2025: MEDLINE, EMBASE, CINAHL and the Cochrane Central Register of Controlled Trials. Only randomised controlled trials were included.
DATA EXTRACTION AND SYNTHESIS: One study out of 197 citations was included in this review.
MAIN OUTCOMES: The outcome measures were morbidity, escalation of care, length of hospital stay, adverse events, mortality due to exacerbation and change in lung function.
RESULTS: We included one study with a total number of participants (n)=43. Participants who received subcutaneous epinephrine showed no significant difference in the asthma clinical score postintervention (3.3 compared with 4.0, respectively), as well as in the hospitalisation rate (risk ratio (RR) 0.38, 95% CI 0.04 to 3.40, p=0.39, n=43) and the need for additional intravenous medications (RR 0.23, 95% CI 0.03 to 1.81, p=0.16, n=43), or predicted increase in peak expiratory flow (PEF) percentage at 2 hours (mean difference -1.00, 95% CI -8.21 to 6.21, p=0.79, n=31).
CONCLUSION: This review demonstrated very low certainty of evidence based on a single paper indicating that subcutaneous epinephrine does not benefit children with acute asthma in terms of asthma clinical score, hospitalisation rate and the need for additional intravenous medications. No significant improvement in PEF percentage was observed after the intervention.
PROSPERO REGISTRATION NUMBER: CRD42023405407.
OBJECTIVES: To assess the safety and efficacy of subcutaneous epinephrine in addition to the standard first-line treatment of acute asthma in children.
DATA SOURCE AND STUDY SELECTION: The following databases were inspected from 1966 to 22 June 2025: MEDLINE, EMBASE, CINAHL and the Cochrane Central Register of Controlled Trials. Only randomised controlled trials were included.
DATA EXTRACTION AND SYNTHESIS: One study out of 197 citations was included in this review.
MAIN OUTCOMES: The outcome measures were morbidity, escalation of care, length of hospital stay, adverse events, mortality due to exacerbation and change in lung function.
RESULTS: We included one study with a total number of participants (n)=43. Participants who received subcutaneous epinephrine showed no significant difference in the asthma clinical score postintervention (3.3 compared with 4.0, respectively), as well as in the hospitalisation rate (risk ratio (RR) 0.38, 95% CI 0.04 to 3.40, p=0.39, n=43) and the need for additional intravenous medications (RR 0.23, 95% CI 0.03 to 1.81, p=0.16, n=43), or predicted increase in peak expiratory flow (PEF) percentage at 2 hours (mean difference -1.00, 95% CI -8.21 to 6.21, p=0.79, n=31).
CONCLUSION: This review demonstrated very low certainty of evidence based on a single paper indicating that subcutaneous epinephrine does not benefit children with acute asthma in terms of asthma clinical score, hospitalisation rate and the need for additional intravenous medications. No significant improvement in PEF percentage was observed after the intervention.
PROSPERO REGISTRATION NUMBER: CRD42023405407.